Treatment of Patients With Advanced Solid Tumors With Oral Agent ORIN1001 and in Combination With Standard of Care.

  • STATUS
    Recruiting
  • End date
    Jun 30, 2023
  • participants needed
    350
  • sponsor
    Orinove, Inc.
Updated on 29 May 2022

Summary

Dose escalation of ORIN1001 in patients with advanced solid tumors.

Dose escalation of ORIN1001 in combination with standard of care in patients with esophageal carcinoma, metastatic breast cancer, hepatocellular carcinoma, metastatic prostate cancer, pancreatic cancer, ovarian cancer and non-small cell lung cancer.

Dose expansion of ORIN1001 as a single agent or in combination with standard of care in patients with advanced solid tumors.

Description

Dose escalation of ORIN1001 administered as a single agent in patients with advance solid tumors. ORIN1001 is administered daily as a tablet.

Dose escalation of ORIN1001 administered in combination with standard of care in patients with esophageal carcinoma, triple negative breast cancer, ER+/HER2- metastatic breast cancer, hepatocellular carcinoma, metastatic castration-sensitive prostate cancer, pancreastic cancer, ovarian cancer and non-small cell lung cancer.

Dose expansion of single agent or combination therapy with ORIN1001 in patients with advanced solid tumors.

Details
Condition Effect of Drug
Treatment ORIN1001
Clinical Study IdentifierNCT05154201
SponsorOrinove, Inc.
Last Modified on29 May 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

The patients must meet all of the following conditions
Male or female, ≥ 18 years of age
Single-agent dose-finding period and single-agent expansion cohort of advanced solid tumors: Patients with advanced solid tumors confirmed by histology or cytology who previously failed standard treatment (including surgery, chemotherapy, radiotherapy or biological therapy) or have no effective standard treatment; dose escalation and expansion period of combination therapy: Histologically or cytologically confirmed advanced breast cancer, hepatocellular carcinoma, prostatic cancer, pancreatic cancer, ovarian cancer, non-small cell lung cancer and esophageal cancer (see the inclusion criteria of each indication for details)
Provide evidence of disease progression or intolerable toxicity as confirmed by the investigator or documented in the medical history before enrollment
Adequate organ functions, including all the following functions: Adequate bone marrow reserve, defined as: Absolute neutrophil count (ANC) ≥ 1.0 × 109/L; lymphocytes count ≥ 0.5 × 109/L; platelet count ≥ 100 × 109/L; hemoglobin ≥ 90 g/L; liver function (except hepatocellular carcinoma cohort): Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), ≤ 3.0 × ULN for patients with Gilbert syndrome; aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 × ULN; ALP ≤ 2.5 × ULN; AST, ALT, ALP ≤ 5 × ULN for liver cancer patients or patients concomitantly with liver metastases; INR and APTT < 1.5 × ULN (patients receiving anticoagulant therapy are required to maintain dose stability within the recent two weeks (liver cancer patients are not allowed to take anticoagulants simultaneously for patients); renal function: Creatinine < 1.5 × ULN, or normal range of serum creatinine or creatinine clearance ≥ 50ml/min/1.73m2. Creatinine clearance is calculated using the Cockroft-Gault formula. Albumin ≥ 30 g/L
Known left ventricular ejection fraction (LVEF) > 50%
Coagulation function: International normalized ratio (INR) and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN
Patients with at least one evaluable lesion (single-agent dose escalation period) and at least one measurable lesion (single-agent dose expansion and combination therapy dose-finding/expansion period) according to RECIST Version 1.1
Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 1
Able to understand and willing to sign an informed consent form prior to the initiation of any study procedures; patients have an expected survival of at least 3 months
Females of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first dose of study drug and agree to practice contraception from 30 days prior to the first dose of study drug through 30 days after the last dose of study drug; male subjects must undergo ligation surgery or agree to practice contraception from 7 days prior to the first dose through 30 days after the last dose of study drug and refuse to donate sperm; failure rate of contraception is < 1% per year, and the typical birth control measures include double-barrier contraception, condom, oral or injectable contraceptives, intrauterine device, etc
Non-hematologic toxicities of prior therapy return to ≤ Grade 1 (NCI-CTCAE version 5.0), except alopecia
Inclusion criteria specific to triple-negative breast cancer (TNBC)
Male or female patients with relapsed or refractory triple-negative breast cancer who have received at least 2 prior lines of therapy or who have no standard treatment or who are unable to benefit from current therapy
ER-, PR-, HER2-
ER+/HER2- breast cancer specific inclusion criteria
Patients diagnosed with ER+, HER2-, postmenopausal (≥ 18 years old) advanced breast cancer who have received one line of treatment, with evidence of local recurrence or metastasis, not suitable for surgical resection or radiotherapy with the purpose of cure, without clinical indication for chemotherapy, postmenopausal women who have not received systemic treatment
Menopause definition
Having received bilateral oophorectomy previously
Age ≥ 60 years
Age < 60 years and amenorrhea for 12 months or more in the absence of chemotherapy, tamoxifen, toremifene, or ovarian suppression, and FSH and estradiol in the postmenopausal range (serum FSH > 40 mIU/mL and estradiol < 20 pg/mL or postmenopausal range as defined by the local laboratory)
If taking tamoxifen or toremifene and aged < 60 years with FSH and estradiol in the postmenopausal range (serum FSH > 40 mIU/mL and estradiol < 20 pg/mL or per the postmenopausal range defined by local laboratory)
Patients must have: At least one measurable lesion according to RECIST 1.1 criteria (a
lesion is considered measurable if it has been treated with radiotherapy or
other local-regional therapy previously and there is clear documentation of
disease progression at the treatment site after therapy completion). If there
is no measurable disease, there must be at least one bone lesion dominated by
lytic bone lesions (patients with no measurable disease and only one lytic
bone lesion who have been previously treated with radiation therapy are
eligible if there is documented evidence of disease progression in the bone
lesion after radiation therapy)
Hepatocellular carcinoma specific inclusion criteria
Histologically or cytologically confirmed hepatocellular carcinoma
Barcelona classification (BCLC) B or C, not suitable for radical therapy (transplantation, surgical resection, ablation, etc.) or local therapy (TACE)
Hepatic function: Child-Pugh score A
Patients with HBV or HCV infection should receive antiviral therapy for 3 months before the enrollment for treatment and should continue to receive antiviral therapy during the trial
Not more than 1 prior systemic therapy
Prostatic cancer specific inclusion criteria
Histologically or cytologically confirmed prostatic adenocarcinoma
Candidates for abiraterone acetate therapy with documented evidence of disease progression (after castrate levels of testosterone (< 50 ng/dl or 1.7 nmol/L) is reached, with at least one of the following: ①Biochemical relapse: PSA increased three times consecutively after an interval of more than 1 week, both increases are above 50% of the low point of PSA, and PSA > 2 ng/ml. ② Radiographic progression: Appearance of new lesions, including two or more new bone metastases on bone scan, or new soft tissue lesions evaluated using RECIST criteria
Surgical or medical castration to achieve testosterone levels < 50 ng/dL (1.7 nmol/L). Subjects who have not previously undergone bilateral orchiectomy must have started treatment with a luteinizing hormone-releasing hormone (LHRH) analogue at least 4 weeks prior to Cycle 1 Day 1 and must continue the treatment during the study
Patients with castration-resistant prostatic cancer who have not received prior chemotherapy
Pancreatic cancer specific inclusion criteria
Definite histologically or cytologically confirmed unresectable pancreatic cancer. Patients with islet cell tumors are excluded
Up to 1 prior systemic therapy (5-fluorouracil (5-FU) or gemcitabine as a radiosensitizer is not counted as a line, provided that there is no sustained toxicity for at least 6 months after the last dose)
Patients should be asymptomatic of jaundice or have completed biliary stent implantation before the first day after the enrollment. Massive or symptomatic ascites should be evacuated before the first day. Pain symptoms should be stable and do not require adjustment of analgesic therapy before the first day of enrollment
Neutrophil count≥ 1.5 × 109/L
Ovarian cancer specific inclusion criteria
Histologically confirmed and documented advanced recurrent ovarian cancer, fallopian tube cancer, and primary peritoneal cancer
Platinum-refractory and platinum-resistant disease must have evidence of radiographic progression of the most recent platinum-based therapy within 6 months, calculated from the date of the last platinum-based therapy dose
Having received one prior line of standard treatment
Non-small cell lung cancer specific inclusion criteria
Histologically confirmed locally advanced or metastatic non-small cell lung cancer (squamous or non-squamous)
Patients who have previously received at least one treatment regimen for locally advanced, unresectable/inoperable or metastatic NSCLC, and can provide evidence of disease progression during or after the last treatment (platinum-based adjuvant chemotherapy and/or neoadjuvant chemotherapy or combination therapy with curative intent (such as chemoradiotherapy)) as well as relapse within 6 months can be counted as a line of therapy
Metastatic/refractory disease documented by imaging (CT scan, MRI, bone scan, etc.), clinical examinations (palpable nodules), or biopsy
If there is no relevant test result of EGFR-, ALK-, the test needs to be completed at a local laboratory and the result is negative
Esophageal cancer specific inclusion criteria
Pathologically confirmed locally advanced recurrent, metastatic, or unresectable advanced esophageal squamous cell carcinoma
At least 1 target lesion is measured by CT scan or MRI according to RECIST 1.1 criteria
Patients who have failed in at least 1 line of standard treatment

Exclusion Criteria

Patients who meet any of the following criteria should not be enrolled in this clinical
study
Having received monoclonal antibody, chemotherapy, radiotherapy, or other
investigational therapy within 4 weeks or 5 half-lives (whichever is shorter) before
the start of dosing. Having received surgery or not recovered from surgery within 2
weeks before starting dose
Central nervous system metastasis or injury without a stable control (patients with
stable disease for more than 3 months who have received intracranial
radiotherapy,there is no need hormone therapy are allowed)
Spinal cord compression was not treated with surgery and/or radical radiotherapy
(previously diagnosed spinal cord compression clinically symptom or stable for ≥ 3
months after treatment is allowed
Leptomeningeal disease; uncontrolled pleural effusion, pericardial effusion, or
ascites requiring repeated drainage; uncontrolled tumor-related pain
Patients who have not recovered from toxic reactions caused by previous anti-tumor
treatment (≥ NCI-CITCAE 5.0 grade 2, except alopecia); patients with uncontrolled
diabetes (patients who are receiving stable insulin regimen or hypoglycemic agent
regimen and are evaluated by specialists to have a stable blood glucose control are
allowed)
Patients with a history of coagulation disorders; patients requiring anticoagulant or
antiplatelet therapy (aspirin dose ≤ 81 mg/d, orally and subcutaneous injection of
low-molecular-weight heparin preventing of deep venous thrombosis is allowed)
The subjects have a history of malignancy other than the indication for inclusion
within the past three years, with the exception of radically treated non-melanoma
basal cell carcinoma of the skin or carcinoma in situ of the cervix
Patients with active infection of hepatitis B or C (except patients with liver cancer)
or human immunodeficiency virus (HIV) infection or active pulmonary tuberculosis or
other known active and/or uncontrolled infection
Patients with serious infections, including but not limited to infectious
complications, bacteremia, and severe pneumonia requiring hospitalization; patients
who received intravenous antibiotics within 2 weeks before enrollment (prophylactic
antibiotics e.g., antibiotics for the prevention of urinary tract infection or chronic
obstructive pulmonary disease are allowed)
Any serious uncontrollable psychological or physical illness that would impair the
patient's ability to follow protocol treatment, including but not limited
to:Symptomatic congestive heart failure (congestive heart failure with New York Heart
Association (NYHA) class ≥ III), unstable angina pectoris, arrhythmia, autoimmune
diseases, infections and mental illness
Pregnant or lactating women. Any patient who gets pregnant during the trial is to be
withdrawn from the study
Patients who have received prior IRE1 inhibitors
Triple negative breast cancer (TNBC) specific exclusion criteria
The investigator does not recommend re-treatment with paclitaxel because of toxicity
ER+/HER2- breast cancer specific exclusion criteria
Patients have risk of life-threatening complications or organ spread in a short term
Known central nervous system uncontrolled or symptomatic metastases, the
leptomeningeal metastasis
(Neo) adjuvant treatment with letrozole or anastrozole within 12 months
Hepatocellular carcinoma specific exclusion criteria
More than 50% of liver is occupied
Bile duct invasion
Main portal vein branch invasion
Moderate to severe ascites with symptoms
HBV DNA level ≥ 500 IU/mL
Patients with untreated or incompletely curable concomitant bleeding, or
gastric/esophageal varices at high risk of bleeding, or bleeding events due to
gastric/esophageal varices within 6 months prior to treatment of the study
Hepatic encephalopathy
Coadministrate anticoagulants
Prostatic cancer-specific exclusion criteria
Previous exposure to cytochrome P450 (cyp) 17 (17α-hydroxylase/C17, 20-lyase)
inhibitors (e.g., abiraterone acetate, Orterone)
Concurrent use known strong cytochrome P450 (cyp) 3a inhibitors and moderate cyp3a
inhibitors. The required washout time is 2 weeks before starting study treatment
Concurrent use known strong cytochrome P450 (cyp) 3a inducers or moderate cytochrome
P450 (cyp) 3a inducers. Treatment washout is 5 weeks for phenobarbital and
enzalutamide and 3 weeks for other agents prior to starting study treatment
Any chronic medical condition requiring systemic doses of corticosteroids greater than
equivalent of 10 milligrams (mg) per day of prednisone acetate
Pancreatic cancer-specific exclusion criteria
The patients have a decline in ECOG, or a greater than 20% decrease in serum albumin
or 10% decrease in body weight at the baseline visit or within 72 hours prior to
enrollment
Patients who have received gemcitabine-containing regimens as standardized adjuvant
chemotherapy or chemotherapy for advanced disease previously
Known hypersensitivity to gemcitabine or adjuvants
The patient is receiving coumarin anticoagulants
Ovarian cancer specific exclusion criteria
Prior allergy or intolerance to liposomal doxorubicin (PLD)
Specific exclusion criteria to non-small cell lung cancer
Prior treat with docetaxel
Patients with hypersensitivity to known docetaxel or adjuvant
Pathological diagnosis of mixed small cell and non-small cell lung cancer, or
carcinoid tumor
Presence of peripheral neuropathy NCI-CTCAE version 5.0 > Grade 2
Specific Exclusion Criteria to esophageal cancer
Presence of peripheral neuropathy NCI-CTCAE version 5.0 > Grade 2
Patients with hypersensitivity to known docetaxel or adjuvant agents (combination
treatment group)
Patients who have received docetaxel within 1 year (combination treatment group)
The tumor has invaded important blood vessels or the investigator judges that the
tumor is very likely to invade important blood vessels during the subsequent study and
cause fatal massive hemorrhage
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note